A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy

Greetta JoensuuCancer Gene Therapy Group, Molecular Cancer Biology Program & Transplantation Laboratory & Haartman Institute & Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland;International Comprehensive Cancer Center Docrates, Helsinki, Finland

Timo JoensuuInternational Comprehensive Cancer Center Docrates, Helsinki, Finland

Nina NupponenMolecular Cancer Biology Program, University of Helsinki, Helsinki, Finland

Mirja RuutuDepartment of Urology, Helsinki University Central Hospital, Helsinki, Finland

Juhani CollanDepartment of Oncology, Helsinki University Central Hospital, Helsinki, Finland

Sari PesonenCancer Gene Therapy Group, Molecular Cancer Biology Program & Transplantation Laboratory & Haartman Institute & Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland;HUSLAB, Helsinki University Central Hospital, Helsinki, Finland

Akseli HemminkiCancer Gene Therapy Group, Molecular Cancer Biology Program & Transplantation Laboratory & Haartman Institute & Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland;HUSLAB, Helsinki University Central Hospital, Helsinki, FinlandCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

We thank Arja Vilkko for superb research nurse support. Akseli Hemminki is K. Albin Johansson Research Professor of the Foundation for the Finnish Cancer Institute. AstraZeneca supported this trial in the form of grants, equipment and drugs. No conflict of interest exists regarding this trial. However, we would like to disclose that Greetta Joensuu and her siblings own AstraZeneca shares (total value < 3000 €).

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy

Information for

Open access

Opportunities

Help and information

A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy

Acknowledgements

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature